Oncologist Discusses First-Of-Its-Kind Treatment Option for Early-Stage Breast Cancer Interviews Available with Elizabeth M Nichols, MD, Assistant Professor of Radiation Oncology at the University of Maryland School of Medicine, Clinical Director, Department of Radiation Oncology at the University of Maryland Medical CenterFriday, Feb. 1, 2019 from 7:00 AM - 12:30 PM ET Early detection and treatment have yielded high survival rates for women diagnosed with early-stage breast cancer. However, standard radiation techniques can present significant challenges for patients, especially those who must undergo weeks of daily treatments. A new FDA-cleared treatment method developed by doctors and scientists at the University of Maryland School of Medicine could provide an alternative for some diagnosed with this disease – one that could shorten radiation treatment from weeks to days. The GammaPod, a unique radiation system designed to treat early-stage breast cancer by targeting the cancer and limiting damage to other organs, is part of a growing movement in oncology to try to reduce the amount of treatment to help curb side effects, improve quality of life and prevent patients from being overtreated. In interviews, Dr. Elizabeth Nichols, MD will discuss early-stage breast cancer, the problem of overtreatment, benefits of partial breast radiation and who is a candidate for the GammaPod. About Elizabeth M Nichols, MD Dr. Nichols is an assistant professor of radiation oncology at the University of Maryland School of Medicine, clinical director of the University of Maryland Medical Center Department of Radiation Oncology and chair of the GammaPod Consortium. Dr. Nichols specializes in treating breast and gynecologic cancers.
Anxiety, It's Time to Go: New Book Ditches the Psychobabble to Remove Anxiety…for Good!
Kevin Mullin’s ‘Anxiety, It’s Time to Go’ calls on the author’s vast experience as an NLP practitioner to help readers identify the root of their anxiety and not only remove it…but rid it for good. Using a series of proven techniques, this breakthrough guide could just be the most com
Ayr, Scotland – Those who suffer from anxiety and its related disorders understand it isn’t just disheartening, but an often-debilitating, life-destroying condition. And even worse, there’s a flood of books on the market conveying half-baked techniques that rarely actually work.
But that all now stops thanks to NLP practitioner Kevin Mullin and his new book, ‘Anxiety, It’s Time to Go’.
Just like the title, Mullins’ breakthrough text marks anxiety’s “grand finale” for its sufferers around the world, as they prepare to step into a new life free of the condition.
Synopsis:
Anxiety, It's Time to Go is not just another self-help book. It is 'the' self-help book. It uses cutting-edge tried and tested methods that have been used time and time again to remove anxiety from people each and every day. Anxiety, It's Time to Go will explain everything in simple terms and then show you exactly how to combat the things that hurt and control us when it comes to anxiety. The easy-to-follow exercise and instructions have been made straightforward without all the psychobabble that most people use. We say it as it is and then show you exactly how to remove it. This might just be the best thing you have done when it comes to beating crippling anxiety once and for all.
“The over-riding goal with this book was to make it as straightforward and actionable as possible, with no fluff and no BS,” explains the author. “The fact of the matter is that anxiety is an epidemic in society these days and, unless someone steps in to do something about it, it’s going to continue destroying lives around the world.”
Continuing, “You need no prior understanding of NLP to use my book to change your life, and you also don’t need to fully understand your own anxiety. If you suffer, or even think you do, what I have to teach will radically improve your mental health and the overall quality of your life. Get a copy today!”
Reviews have been extremely positive. One reader writes, “I was given the book to read and I loved it. It was one of those books that I did not want to put down but equally did not want to finish, as I was enjoying it too much (like saving a new dress 'for best'). It was all so simple, it made sense and it worked!!! Now, I am not going to elaborate more, because I am now too busy living anxiety-free! Too busy enjoying life. Planning life. Too happy to even think about the old me who wasted so much time feeling anxious, stressed, miserable, not wanting to be here. So, read it for yourself.”
Kevin Mullin enlisted in the British Army aged fifteen years and eight months. He served in several conflict areas and operations around the globe, then at the age of thirty-four, he left the service and became a private military operator. Kevin was contracted to the United States Department of Defense, securing and protecting US Military bases and assets in Afghanistan. Kevin worked there for four years before moving to one of the most valuable targets in Afghanistan in the heart of Kabul – The Serena Hotel. Kevin studied NLP within the British Army and gained a wealth of knowledge and experience, training the trainers in the methods of approaches to NLP. Having suffered the loss of both his brother and mother, he was crippled with anxiety for many years. Kevin searched relentlessly for new, dynamic ways to beat it.
Having taken an apprenticeship with Ali Campbell, Kevin finally found what he was looking for. He understudied and role modelled Ali to great effect. In June 2017, Kevin opened his very own NLP practice based in Central Scotland. The practice has received rave reviews about Kevin’s new, dynamic and direct approach. He has helped thousands of clients become anxiety-free. Kevin has gained plaudits from Italy, Dubai and America for his dynamic and enthusiastic approach to motivational speaking and helping businesses and organisations flourish and grow. He is also a full-time parent. He raises his children with the approach he takes in life and in his crusade to help everyone in the battle with anxiety. Drive, determination and a vigour unparalleled in this modern age.
GeneNews Publishes Data on ColonSentry® in Colorectal Cancer Risk Assessment
Study demonstrates validity of blood-based biomarker test as an adjunct method to colon cancer screening tests in non-compliant patient populations
TORONTO, Jan. 28, 2019 /CNW/ - GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") today announced it has published a new study that further validates the stability of its proprietary test, ColonSentry®, as a tool to risk stratify patients who are non-compliant with any form of Colorectal Cancer screening and prioritize patients who should be referred directly for colonoscopy versus other modalities for colorectal cancer screening. The paper, "Stability of the ColonSentry Colon Cancer Risk Stratification Test" appears in the current online edition of International Journal of Disease Markers.
ColonSentry is a proprietary liquid biopsy test that uses advanced gene expression technology for the early identification of Colorectal Cancer (CRC). Initially developed in 2008 from a clinical study involving approximately 10,000 subjects in North America, ColonSentry was broadly commercialized in 2014 and has been administered to over 100,000 patients throughout the U.S. The ColonSentry test is the first commercially available test that uses GeneNews proprietary science, the Sentinel Principle. The Sentinel Principle is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body and underpins the Aristotle program, which is focused on detecting ten cancers from a single sample of blood.
The study's authors compared real-life distribution of the results against the model that was initially developed and reviewed them in the context of measurement stability, and to evaluate the validity of the assumptions made during the construction of the mathematical model. The model's assumption of two subpopulations, one with colorectal cancer at 0.7% prevalence, and the other without colorectal cancer at 99.3% prevalence, fit the data within the expected measurement tolerances. Research also explores enhancement of the model to address a precancerous polyp phase subpopulation, and how the test results can be used to identify patients who should be referred directly for colonoscopy versus other modalities for colorectal cancer screening. The study confirmed that ColonSentry can be used to determine, from a blood sample, whether patients are at elevated risk for colorectal cancer and detects left and right-sided lesions with similar sensitivity. ColonSentry can be considered for use as an alternative method in non-compliant patient populations.
According to the study's lead author, Robert Burakoff, MD, Site Chief for the Division of Gastroenterology and Hepatology at New York-Presbyterian Lower Manhattan Hospital and Weill Cornell Medicine, "The clinical utility of ColonSentry is significant. A routine blood test for patients who have yet to comply with any form of colorectal cancer screening can be a game-changer in identifying those at elevated risk for the disease and motivating them to have their colonoscopy. In addition, routine use of a blood test that detects both left-sided and right-sided lesions can increase the effectiveness of colorectal cancer screening by revealing the potential presence of neoplasms in advance of colonoscopy."
James R. Howard-Tripp, GeneNews' Chairman and CEO further commented "Finding colorectal cancer early is critical and alters the 5-year survival rate from 11% if found late, to 91% if found early. Additionally, a diagnostic test must be convenient and patient friendly if we are going to successfully address the 33% of patients who are non-compliant with CRC screening. ColonSentry fulfills this role, and this confirmatory study on 100,000 at-risk patients demonstrates the robust nature of the test."
ColonSentry requires a simple, in-office blood draw. If the ColonSentry score is elevated in a patient at average risk, there is an increased probability the patient may have a pre-cancerous lesion or colorectal cancer. Patients with an elevated ColonSentry score are referred for further evaluation.
According to the American Cancer Society, Colorectal cancer is the third most common cancer diagnosed in men and women in the U.S. Approximately 140,000 people are diagnosed each year, and more than 50,000 people are estimated to die from the disease.
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health out-comes through the early diagnosis of disease. Our Richmond, Virginia-based clinical reference lab, Innovative Diagnostic Laboratory (IDL) specializes in advanced molecular diagnostics that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
SOURCE GeneNews Limited
Why are Hot Showers So Beneficial for Sore Muscles? After a big workout or another major physical activity, such as for moving furniture or packing boxes, muscles can become tight, sore, and painful. Individuals may notice that they have tight necks, sore arms and legs, and decreased flexibility. However, a hot, steamy shower may be just right for getting rid of sore muscles and getting back to normal within the next day or two.
Loosen Tight, Sore Muscles The first and most obvious benefit of hot showers for muscles is their loosening of tight muscle fibers. After a big workout, the muscles often become tight, tense, and inflexible because of the buildup of lactic acid in them. Hot water helps to open up the fibers, allowing lactic acid to be washed away and decreasing any pinching sensations around nerves that run through the muscles.
Increase Blood Circulation Hot water also improves circulation by widening the blood vessels. When more blood can get to an area, the area will heal faster, and muscle fibers will find it easier to repair themselves. A hot shower can also be beneficial in the morning before a workout because it helps to loosen up the body with improved circulation, limiting the chance for injuries during a workout.
Get Hot Water All the Time Family members who are not getting enough hot water to complete a relaxing shower or who find that the hot water is gone before may feel frustrated. This may mean that you might possibly need to look into getting a new water heaterfor the household. New Energy-Star rated water heaters can save money while also heating water faster than ever. Individuals should be sure to choose a heater capacity that matches the number of people in the household.
Decrease Overall Stress Hot showers are about more than just physical benefits for muscles. As the hot water washes over the body, a sensation of letting go often occurs as well, leading to less stress mentally. Decreased stress and anxiety can also indirectly help loosen muscles. Of course, hot showers are beneficial for more than just muscles. They can also open congested sinuses, improve skin color and tone, and warm up a body that is cold during the winter. However, when used for sore muscles, hot showers can be incredibly beneficial by warming up the entire body at once while also including the calming effect of the water running over the skin. For a non-serious injury, heat can truly be a powerful and effective treatment.
General Manager Robert De Clark Announces Four New Appointments at Homewood Ravensview
Leading interdisciplinary experts join Homewood's groundbreaking new mental health and addiction treatment centre in BC in advance of its opening in Spring 2019
VICTORIA, Jan. 24, 2019 /CNW/ - Homewood Health, Canada's leader in mental health, trauma and addiction treatment, welcomes on board four highly-skilled and accomplished experts to Ravensview, its newest treatment centre located in North Saanich, British Columbia.
Robert De Clark, General Manager of Homewood Ravensview, is proud of the talented team coming together to lead the development and delivery of the facility's innovative programs.
"We are committed to supporting our clients in achieving positive outcomes, and providing medically-led, evidence-based care," says De Clark. "Homewood Ravensview is committed to continuous, positive collaboration with the community and we're thankful to all the Islanders who have welcomed our presence."
Joining Robert De Clark and Dr. Lyn Macbeath, (previously announced as Ravensview's medical director) are the following new medical and clinical leaders at Homewood Ravensview.
In the role of Clinical Director, De Clark welcomes Dr. Michael Berry R.PSYCH. Dr. Berry is a clinical psychologist with expertise in a variety of evidence-based assessments and treatments used to address mood/anxiety disorders, addictive behaviours, personality disorders and family issues. The clinical approach Dr. Berry uses is humanistic and integrative, taking a highly compassionate, down-to-earth approach, using humour, warmth, and evidence-based practices to help people.
Appointed to the role of lead psychiatrist is Dr. Kiri Simms BSCN, MD, FRCP(C). Dr. Simms is a renowned psychiatrist in BC and a Fellow of the Royal College of Physicians & Surgeons of Canada and an expert in emergency and crisis intervention, addiction treatment, medical psychiatry and the treatment of anxiety disorders. Her previous professional postings include clinical positions at the Douglas Mental Health University Institute in Montreal and the Vancouver Island Health Authority (Island Health). As a long standing and respected member of the Victoria medical community, Dr. Simms brings her extensive local experience and knowledge to Ravensview.
Dr. Paul BeckettMD, CCFP, DABAM, FASAM, CSAM joins Ravensview in the role of Addiction Physician. A specialist in addiction and family practice, Dr. Beckett worked for a decade as an ER physician and also directed medical care at many addiction centres (Maple Ridge Treatment Centre, Creekside Withdrawal Management and Hannah House). For over eleven years, Dr. Berry also provided physician services to multiple BC Correction Centres.
Alexis Winter RPN, BA has been appointed as Ravensview's Director of Nursing. Ms. Winter is a Registered Psychiatric Nurse and a Master's Degree Candidate in Psychiatric Nursing who has extensive experience working with interdisciplinary health care teams in hospital, tertiary care and community outreach settings. Ms. Winter has also served as a director and the vice-chair of the College of Registered Psychiatric Nurses of British Columbia.
Homewood Health President and CEO, Jagoda Pike is equally enthusiastic about the Ravensview team. "Our new medical and clinical leaders reflect Homewood's core values, and we are honoured to welcome them to Ravensview," said Ms. Pike. "Their leadership and contribution to innovative program development will ensure life-changing treatment experiences for our many clients seeking a return to good health."
For more information about Homewood Ravensview or to learn additional details about the team, please visit the Centre's newly launched site: www.ravensview.com
About Homewood Health
Homewood Health is Canada's leader in mental health and addiction services. With more than 135 years of experience, Homewood achieves outstanding outcomes through its national network of more than 4,500 employees and clinical experts. Homewood's complete suite of services includes organizational wellness, employee and family assistance programs, assessments, outpatient and inpatient treatment, recovery management, return to work and family support services, all customized to meet the needs of individuals and organizations. Homewood Health is redefining mental health and addiction services to help Canadians live healthier, more productive and more fulfilling lives.
About Homewood Ravensview Homewood Ravensview, part of Homewood Health, offers treatment for mental health, addiction and concurrent conditions. The Centre is located on 28 acres of forested hillside on Vancouver Island's Saanich Peninsula and focuses on creating individualized client experiences. Homewood Ravensview features forest and ocean views from private and semi-private bedrooms, suites and welcoming common areas. Homewood Ravensview is scheduled to open in spring of 2019 with 75 beds and will employ more than 80 full-time staff.
STONEFIELD VILLA RESORT ANNOUNCES ANGELA SIMMONS FITNESS SWEEPTAKES
SOUFRIERE, SAINT LUCIA - (Jan 24th, 2019) Stonefield Villa Resort, a premiere health and wellness boutique property nestled at the base of Saint Lucia’s famous Pitons has partnered with television personality and philanthropist, Angela Simmons to launch an all new online sweepstakes now through February 8th, 2019.
The Stonefield Villa Resort Sweepstakes offers followers a chance to win a five-night vacation package valued at $5,000 USD.
To enter the sweepstakes, participants must follow @AngelaSimmons and @StonefieldVillaResort on Instagram, like the sweepstakes video on Instagram, tag your wellness partner, and fill out the contest entry form.
"Stonefield Villa Resort is my Secret Getaway
to Unwind, ReFresh and ReCharge”.
- Angela Simmons -
“Angela has been a friend of our resort for some time and we were super excited when she returned in January to launch her year of wellness and this sweepstakes", said Cybelle Brown, Managing Director of Sales & Marketing. "Repeat business at Stonefield has grown substantially, many guests come back year after year to reconnect in our lush tropical environment. Stonefield has completely rebranded itself to a best in class health and wellness resort. We believe that this strategic partnership with Angela Simmons will attract more like-minded wellness travellers”.
Sweepstakes Grand Prize Includes:
Five Nights Luxury Accommodations
Private One Bedroom, Air-Conditioned Villa with Private Pool
Breakfast & Dinner at our Farm-to-Table Mango Tree Restaurant
Saint Lucia Sulphur Springs Mud Bath Excursion
Free Wi-Fi in room and public areas
Unbeatable Caribbean Sea and Piton Views
Transportation to and from the Airport
The sweepstakes runs in the United States and Canada through to February 8th, 2019. The winner will be chosen based on a random drawing among eligible entries that have entered the sweepstakes. The winner will be selected and announced on February 13th, 2019. For full rules on this sweepstakes please click here.
Stonefield Villa Resort is one of the most desirable destinations for the discerning Caribbean traveller. This 17-villa boutique property is nestled at the base of Saint Lucia’s Pitons overlooking the Caribbean Sea. Guests relax, luxuriate and rejuvenate in spacious secluded villas each with large private pools, outdoor garden showers, large verandas and extraordinary views of the Petit Piton and the Caribbean Sea. The resorts’ full-service spa, gym and yoga studio has attracted fitness and wellness groups globally offering annual retreats for exceptional rejuvenation. Consistently rated over four stars on Trip Advisor, Stonefield Resort and Spa has become an award-winning annual vacation escape for visitors all over the world.
Baylis Medical Launches First-of-its-Kind Large Access Transseptal Dilator
TORONTO, Jan. 23, 2019 /CNW Telbec/ - Baylis Medical announced today the Canadian launch and first clinical use of its ExpanSure™ Transseptal Dilation System. The device combines a sheath and dilator into a single tool, and facilitates larger dilation compared to a standard fixed curve sheath.
The larger dilation optimizes left-heart procedures such as left-atrial appendage closures and balloon ablations for atrial fibrillation, which require a large sheath to cross the heart's septum from the right atrium. The ExpanSure dilator aims to eliminate use of added force or the introduction of additional devices to achieve crossing, which are often necessary when a larger dilation area is needed. This could result in possible consequences for the patient.
"Baylis is pleased to offer a device uniquely designed to optimize transseptal access, allowing the physician's primary focus to remain on delivering the necessary therapy to the patient," said Neil Godara, Director of Research and Development at Baylis Medical.
A single, streamlined device without the traditional dilator-sheath transition also helps provide access in cases where a patient's fibrotic septum makes transseptal access challenging. This was the case in one of the device's first clinical uses.
"Following several attempts to introduce sheaths through the patient's fibrous septum, access was only made possible by the ExpanSure dilator's streamlined design. It provided the necessary access when other sheaths could not, while the larger dilation allowed the remainder of the procedure to take place," said Cardiologist Dr. Peter Leong-Sit, Investigator with the Cardiac Arrhythmia Network of Canada (CANet).
Baylis is part of CANet's network of industry partners, which provides important opportunities to validate its devices with leading physicians.
"Collaboration with companies like Baylis Medical are key to advancing the delivery of care for patients facing cardiac arrhythmia," said Dr. Anthony Tang, CEO of CANet. "Together, we can ensure that physicians have access to meaningful solutions to the life-threatening issues patients may be facing."
Development of the ExpanSure dilator was made possible by support from the Federal Economic Development Agency for Southern Ontario's Advanced Manufacturing Fund (FedDev Ontario).
"In 2015, FedDev Ontario announced an investment of $15.2 million for Baylis Medical to accelerate the development and commercialization of leading-edge medical devices for use by doctors during heart procedures," said the Honourable Navdeep Bains, Minister of Innovation, Science, and Economic Development and Minister responsible for FedDev Ontario. "Congratulations to Baylis Medical on the launch of an innovative product that will positively impact treatment of patients around the world and expand international markets for made-in-Canada technologies."
The ExpanSure™ Transseptal Dilation System is expected to launch in the United States in early 2019.
About Baylis Medical
Baylis Medical is a world leader in the development and commercialization of high-performance cardiology devices that help physicians deliver life-changing therapies to patients. Headquartered in Canada, and with offices world-wide, our clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com and connect with us on Twitter, LinkedIn and Instagram.
Home automation expert’s first smart scale syncs with popular fitness apps, allows unlimited users to track and set goals, and measures eight body metrics
SOUTH BEND, IN (Jan. 23, 2019) - Home automation expert RolliBot recently unveiled its Rollifit line of digital smart scales during CES 2019. The F8, the first in the Rollifit line, is Bluetooth ready and uses a free companion app to track eight different body metrics but is also compatible with popular fitness apps like Fitbit and Google Fit.
The Rollifit’s app sets it apart from other digital scales by allowing for the creation of unlimited user profiles making it ideal for personal trainers and nutritionists. The app allows users to set goals, track and measure weight, BMI, BMR, body fat percentage, water percentage, muscle mass, bone mass and visceral fat, making the scale a true body composition analyzer. R
When it comes to achieving fitness goals, visually tracking progress is much more effective than one-time standalone measurements. The Rollifit app can be used to monitor user trends in each of its eight categories as well as set goals, provide health tips and more.
The Rollifit F8 uses four precision ITO film biometric sensors for more accurate readings than traditional electrode sheets. Constructed from conductive tempered glass, the F8 supports up to 400 pounds and boasts a sleek, modern design that will complement any home, gym or office.
The Rollifit F8 retails for $55 and is available now for an introductory price of $49.99.
ABOUT ROLLIBOT We are RolliBot. We want to make your home work for you so you can sit back and relax. We believe that home automation should be simple and easy to use, so we are designing the next generation of home automation products that simplify your days so you can enjoy the finer things in life.
Morneau Shepell to announce new research findings at its 8th annual workplace mental health summit in Toronto
Employers Connect 2019 will be held in eight cities across the country
TORONTO, Jan. 23, 2019 /CNW/ - Employees report higher stress and greater isolation than five years ago. Morneau Shepell's latest survey on workplace mental health found that although workplace stigma regarding mental health has decreased, it remains prevalent. Still, improved workplace approaches to mental health are positively impacting employees who agree their organization creates an environment that supports mental wellness on the job.
At Employers Connect, Morneau Shepell will reveal its in-depth research findings and share insights from leading Canadian employers on how organizations can support their employees' overall well-being, including physical, mental, social and financial wellness.
Morneau Shepell invites members of the media to attend Employers Connect and be among the first to hear the new research.
Toronto event details
What:
Employers Connect 2019, 8th annual workplace mental health summit
When:
Wednesday, January 30, 2019, from 8:00 to 10:00 a.m. ET (presentations begin at 8:30 a.m.)
Employers Connect Toronto will feature the following speakers:
•
Nigel Branker, President, Health and Productivity Solutions and Executive Vice President, Morneau Shepell
•
Paula Allen, Vice President, Research and Integrative Solutions, Morneau Shepell
•
Orlando Da Silva, Senior Crown Counsel, Serious Fraud Office, Ontario Ministry of the Attorney General
•
Tanya Hickey, Senior Manager, Corporate Health and Safety Strategies, Ontario Power Generation
This event is open to media and Morneau Shepell clients by invitation only.
Employers Connect events are being held across the country in Vancouver, Calgary, Toronto and Halifax on January 30, in Edmonton and Ottawa on January 31, in Montreal on February 20 and in Quebec City on March 19. To join the conversation online, tweet us @Morneau_Shepell #EmployersConnect2019 #MentalHealth.
About Morneau Shepell Morneau Shepell is the only human resources consulting and technology company that takes an integrated approach to employee well-being, health, benefits and retirement needs. The Company is the largest administrator of retirement and benefits plans and the largest provider of integrated absence management solutions in Canada. LifeWorks by Morneau Shepell is a total well-being solution that combines employee assistance, wellness, recognition and incentive programs. As a leader in strategic HR consulting and innovative pension design, the Company also helps clients solve complex workforce problems and provides integrated productivity, health and retirement solutions. Established in 1966, Morneau Shepell serves approximately 24,000 clients, ranging from small businesses to some of the largest corporations and associations. With more than 4,500 employees in offices worldwide, Morneau Shepell provides services to organizations around the globe. Morneau Shepell is a publicly-traded company on the Toronto Stock Exchange (TSX: MSI). For more information, visit morneaushepell.com.
SOURCE Morneau Shepell Inc.
Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes
An estimated 3.1 million Canadians live with type 2 diabetes, half of whom do not achieve adequate blood sugar control1,2,3
Once-daily Xultophy® combines insulin degludec and liraglutideto help patients achieve blood glucose targets, with a well-established safety profile4
MISSISSAUGA, ON, Jan. 23, 2019 /CNW/ - Novo Nordisk announced today that Xultophy® (insulin degludec + liraglutide injection), a once-daily, fixed-ratio combination treatment in a pre-filled pen, is now available across Canada for the treatment of type 2 diabetes mellitus.4 Of the 3.5 million Canadians with diabetes in Canada, it is estimated that 90 per cent live with type 2.1,2
"When type 2 diabetes is not optimally managed, it may lead to a number of health issues, including heart diseases, stroke, kidney disease, blindness, nerve damage, leg and foot amputations, and death," says Dr. Irving Gottesman, Endocrinologist, Trillium Health Partners, Credit Valley Hospital, and Assistant Professor, University of Toronto. "Studies have shown that half of Canadians with type 2 diabetes are not currently meeting suggested glycemic targets. A fixed-ratio combination treatment that can make their therapy less complicated can help them meet their targets while reducing the risk of hypoglycemia and possibly reducing weight gain."
A 2015 study found differences in how physicians and patients perceived 'control' with regards to diabetes management.5Investigators found physicians prioritized HbA1c levels, complications from diabetes and frequency/severity of hypoglycemia in determining whether diabetes is well controlled.5 However, the study found that those living with diabetes considered factors including energy levels, insulin units per day and predictability of life among factors of most importance.5 The difference suggested a need for enhanced communication between patients and physicians to improve diabetes management.5
"Having an open dialogue with patients who are not meeting their blood glucose targets during consultations may provide important insights into helping people living with type 2 diabetes achieve targets based on a variety of factors that are most important to the patient," says Dr. Irving Gottesman.
Xultophy® was approved by Health Canada in April 2018. Xultophy® is indicated in Canada as an adjunct to lifestyle modifications for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic control.4 Xultophy® can be taken independent of meals, at any time of day, preferably at the same time of the day.4
About the DUAL™ Clinical Development Program The approval of Xultophy® was based on efficacy and safety data from the DUAL™ (Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes) clinical development program. In three DUAL™ trials involving 1,393 randomized adults with type 2 diabetes, patients who were inadequately controlled on liraglutide or insulin glargine and switched to Xultophy® achieved significant reductions in HbA1c.4 For adults inadequately controlled on insulin glargine and insulin degludec, Xultophy® demonstrated clinically significant greater HbA1c level reductions from baseline (-1.83% for the Xultophy® group vs -1.22% for the insulin glargine group and -1.96% for the Xultophy® group vs -0.97% for the insulin degludec group).4
The most frequently reported adverse reactions during treatment with Xultophy® were hypoglycemia and gastrointestinal adverse reactions, of which nausea was the most frequently reported and declined as treatment continued.4
About Xultophy® Xultophy® is a once-daily single injection fixed-ratio combination of long-acting insulin degludec and the GLP-1 RA liraglutide in one pen.
Insulin degludec lowers blood glucose by facilitating glucose uptake upon binding to insulin receptors on muscle and fat cells and simultaneously inhibiting hepatic glucose output.4 Liraglutide stimulates insulin secretion and decreases glucagon secretion in a glucose-dependent manner.4
About Novo Nordisk Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.ca, Twitter, YouTube.
Brod M, et al. Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom. 2016 Jun;32(6):981-9. Accessed Dec 5, 2018. https://www.ncbi.nlm.nih.gov/pubmed/26849483
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
